Developer docs
API playgroundTry for free, no card

Search company profiles

Chrysea

Full company profile

uuid00068yz

Namestring
Chrysea
Websiteurl
chrysealabs.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Chrysea is a Dublin, Ireland-based biotechnology company founded in 2019 that develops nutritional interventions supported by clinical research for anti-aging and longevity applications. The company operates with a 1-10 person team and is privately held. Its core technology platform combines proprietary synthetic biology and biopharmaceutical development capabilities, significantly strengthened by the February 2024 acquisition of Rodon Biologics from Iberfar Group, which brought over 20 years of biomanufacturing and protein engineering experience into the company.

Chrysea's lead commercial product is Sprevive, a high-purity spermidine complex positioned as a bridge between longevity science and evidence-based clinical application. The product carries GRAS recognition and standardized dosing. In May 2026, Chrysea entered an exclusive US commercialization partnership with nuBioAge to distribute Sprevive through healthcare practitioners and pharmacies, shifting the company's go-to-market from wellness supplements toward clinician-guided longevity care. Concurrently, Chrysea is conducting a clinical study with Mount Sinai researchers evaluating Sprevive's effects on immune and metabolic function, intended to underpin evidence-based clinical claims.

The business model is built on clinical-channel distribution of proprietary longevity nutraceuticals rather than direct-to-consumer sales. Chrysea's primary customer segment is US healthcare practitioners and pharmacies reached through its nuBioAge distribution partner. The company does not publicly disclose pricing, revenue, or funding. Beyond Sprevive, the Rodon Biologics platform provides capability breadth in biomanufacturing, protein engineering, and sustainable product development, suggesting a longer-term ambition to expand into a broader bioproducts portfolio, though current monetization is concentrated in a single product line.

Short descriptiontext

Chrysea is a Dublin-based biotechnology company developing clinically-supported longevity interventions, commercializing its lead product Sprevive (a high-purity spermidine complex) through US healthcare practitioners and pharmacies via an exclusive partnership with nuBioAge.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersDublin, Ireland
HQ citystring
Dublin
HQ countrystring
Ireland
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
longevity therapeutics, biopharmaceutical supplements, synthetic biology manufacturing, high-purity spermidine, clinical nutrition products
Industry1 code
PRIMARYHLAKAOAD
Male Reproductive & Sexual Medicine (Andrology)
NAICS code1 code
  • Medicinal and Botanical Manufacturing325411
SIC code1 code
  • Medicinal Chemicals & Botanical Products2833
Product category
Longevity Biopharmaceuticals
Social media profiles1 record
Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Operations, Personnel, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Sprevive
Description

A high-purity spermidine complex developed for longevity and clinical applications, positioned as a bridge between longevity science and evidence-based clinical care.

longevity.technology
Core offering1 text field

Chrysea develops and commercializes high-purity spermidine-based nutritional interventions targeting aging and longevity. Through its acquired biomanufacturing arm Rodon Biologics, the company produces Sprevive, a proprietary high-purity spermidine complex, which it distributes to healthcare practitioners and pharmacies for clinician-guided care.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Chrysea is a biotechnology company operating with a multi-product portfolio focused on synthetic biology and biopharmaceutical development. The company operates through acquired capabilities (Rodon Biologics, bringing biomanufacturing and protein engineering expertise) and proprietary product development (Sprevive, a high-purity spermidine complex for longevity care). The portfolio spans wellness supplements transitioning toward clinician-guided clinical applications, supported by Mount Sinai research partnerships.

Product and service1 record
1Sprevive
CategoryLongevity Nutrition / Spermidine Supplement
Description

A proprietary high-purity spermidine complex developed as a nutritional intervention for aging and longevity, distributed to healthcare practitioners and pharmacies for clinician-guided patient care.

Partnership3 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-05-01
Description

Partnership to bring Sprevive (high-purity spermidine complex) into US clinical settings. nuBioAge received exclusive rights to commercialize the product through healthcare practitioners and pharmacies, representing a shift from wellness supplements toward clinician-guided longevity care.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-05-01
Description

Chrysea is conducting a study with Mount Sinai researchers to explore how Sprevive supports immune and metabolic function, positioning the product as a bridge between longevity science and evidence-based clinical application.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-02-14
Description

Chrysea acquired Rodon Biologics from Iberfar Group to strengthen capabilities in synthetic biology and biopharmaceutical development. The acquisition enables expansion in biomanufacturing, protein engineering, and sustainable product development.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Elysium Health develops and commercializes clinically-validated longevity supplements (e.g., NAD+ boosters) sold through both DTC and clinician channels. It is the closest analogue to Chrysea's positioning of a science-backed, clinically-tested longevity bioactive sold to health-conscious consumers and practitioners.

TypeDirect peer
Description

Tally Health markets longevity-focused supplements and biological-age testing directly to consumers and partners. It overlaps with Chrysea in the science-led longevity nutraceutical category targeting the same health-conscious, longevity-curious buyer.

TypeDirect peer
Description

Insilico Medicine is a longevity and aging-disease biotech combining AI-driven discovery with internal development pipelines. It is comparable to Chrysea as a science-first longevity company pursuing clinically-validated interventions rather than commodity supplements.

TypeDirect peer
Description

BioAge Labs develops therapeutics targeting the biology of aging, including metabolic and immune function pathways relevant to longevity. It shares Chrysea's positioning at the intersection of longevity science, immune/metabolic mechanisms, and clinical development.

TypeDirect peer
Description

Juvenescence is a longevity-focused biotech that develops and invests in compounds targeting aging biology. It is comparable as a multi-program longevity company pursuing clinically-validated aging interventions rather than generic supplements.

TypeDirect peer
Description

Longeveron is a clinical-stage biotech developing cellular therapies for aging-related and rare diseases. It overlaps with Chrysea in the clinical longevity therapeutics space targeting biological aging mechanisms.

TypeDirect peer
Description

Human Longevity Inc. combines longevity-focused health intelligence, diagnostics, and clinical programs. It is comparable to Chrysea as a science-driven longevity company building premium clinical channels around aging biology.

TypeBroad incumbent
Description

Ginkgo Bioworks is a large synthetic biology platform that programs cells for bioactives, flavors, and industrial biotech. It overlaps with Chrysea on the synthetic biology and biomanufacturing capability stack acquired via Rodon Biologics.

TypeBroad incumbent
Description

Codexis develops engineered enzymes and biomanufacturing processes for pharmaceuticals and sustainable chemicals. It is comparable to Chrysea/Rodon on the protein engineering and biomanufacturing capability dimension, though serving pharma and industrial customers rather than direct longevity consumers.

TypeBroad incumbent
Description

Novonesis is a global industrial biotechnology leader in enzyme and microbial fermentation-based manufacturing. It is comparable to Chrysea on the fermentation-driven biomanufacturing and protein engineering capability axis, operating at much larger scale across multiple end markets.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Chrysea

Longevity Biopharmaceuticalschrysealabs.com

Chrysea is a Dublin-based biotechnology company developing clinically-supported longevity interventions, commercializing its lead product Sprevive (a high-purity spermidine complex) through US healthcare practitioners and pharmacies via an exclusive partnership with nuBioAge.

What Chrysea does

Chrysea is a Dublin, Ireland-based biotechnology company founded in 2019 that develops nutritional interventions supported by clinical research for anti-aging and longevity applications. The company operates with a 1-10 person team and is privately held. Its core technology platform combines proprietary synthetic biology and biopharmaceutical development capabilities, significantly strengthened by the February 2024 acquisition of Rodon Biologics from Iberfar Group, which brought over 20 years of biomanufacturing and protein engineering experience into the company.

Chrysea's lead commercial product is Sprevive, a high-purity spermidine complex positioned as a bridge between longevity science and evidence-based clinical application. The product carries GRAS recognition and standardized dosing. In May 2026, Chrysea entered an exclusive US commercialization partnership with nuBioAge to distribute Sprevive through healthcare practitioners and pharmacies, shifting the company's go-to-market from wellness supplements toward clinician-guided longevity care. Concurrently, Chrysea is conducting a clinical study with Mount Sinai researchers evaluating Sprevive's effects on immune and metabolic function, intended to underpin evidence-based clinical claims.

The business model is built on clinical-channel distribution of proprietary longevity nutraceuticals rather than direct-to-consumer sales. Chrysea's primary customer segment is US healthcare practitioners and pharmacies reached through its nuBioAge distribution partner. The company does not publicly disclose pricing, revenue, or funding. Beyond Sprevive, the Rodon Biologics platform provides capability breadth in biomanufacturing, protein engineering, and sustainable product development, suggesting a longer-term ambition to expand into a broader bioproducts portfolio, though current monetization is concentrated in a single product line.

Chrysea firmographics

Firmographics
Name
Chrysea
Website
https://chrysealabs.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
1–10 employees
Short description
Chrysea is a Dublin-based biotechnology company developing clinically-supported longevity interventions, commercializing its lead product Sprevive (a high-purity spermidine complex) through US healthcare practitioners and pharmacies via an exclusive partnership with nuBioAge.
Ownership category
akta.pro rank

Chrysea industry classification

Industry
Product category
Longevity Biopharmaceuticals
NAICS
Medicinal and Botanical Manufacturing (325411)
SIC
Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAKAOAD
Male Reproductive & Sexual Medicine (Andrology)

Keywords

  • Longevity therapeutics
  • Biopharmaceutical supplements
  • Synthetic biology manufacturing
  • High-purity spermidine
  • Clinical nutrition products

Where Chrysea is headquartered

Location

Headquarters

HQ city
Dublin
HQ country
Ireland
HQ region
Europe

Markets served

Chrysea business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Operations, Personnel, Marketing or Sales

Distribution channels1 record

Chrysea product offering

Product offering

Core offering

Chrysea develops and commercializes high-purity spermidine-based nutritional interventions targeting aging and longevity. Through its acquired biomanufacturing arm Rodon Biologics, the company produces Sprevive, a proprietary high-purity spermidine complex, which it distributes to healthcare practitioners and pharmacies for clinician-guided care.

Product overview

Chrysea is a biotechnology company operating with a multi-product portfolio focused on synthetic biology and biopharmaceutical development. The company operates through acquired capabilities (Rodon Biologics, bringing biomanufacturing and protein engineering expertise) and proprietary product development (Sprevive, a high-purity spermidine complex for longevity care). The portfolio spans wellness supplements transitioning toward clinician-guided clinical applications, supported by Mount Sinai research partnerships.

Differentiator

Problem solved

Functional benefit

Brands

  • Sprevive: A high-purity spermidine complex developed for longevity and clinical applications, positioned as a bridge between longevity science and evidence-based clinical care.

Products and services

  • Sprevive A proprietary high-purity spermidine complex developed as a nutritional intervention for aging and longevity, distributed to healthcare practitioners and pharmacies for clinician-guided patient care.

Companies that use Chrysea

Customer profile

Segments1 record

Ideal customer profiles1 record

Chrysea technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Chrysea partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • nuBioAgecoreChannel Partner/ Reseller/ Distributor · 1 May 2026Partnership to bring Sprevive (high-purity spermidine complex) into US clinical settings. nuBioAge received exclusive rights to commercialize the product through healthcare practitioners and pharmacies, representing a shift from wellness supplements toward clinician-guided longevity care.
  • Mount SinaiminorStrategic or Co-development Partner · 1 May 2026Chrysea is conducting a study with Mount Sinai researchers to explore how Sprevive supports immune and metabolic function, positioning the product as a bridge between longevity science and evidence-based clinical application.
  • Rodon BiologicscoreStrategic or Co-development Partner · 14 February 2024Chrysea acquired Rodon Biologics from Iberfar Group to strengthen capabilities in synthetic biology and biopharmaceutical development. The acquisition enables expansion in biomanufacturing, protein engineering, and sustainable product development.

Recent moves5 records

Expansion highlights5 records

Chrysea competitors and assessment

Company assessment

Direct peers

  • Elysium Health: Elysium Health develops and commercializes clinically-validated longevity supplements (e.g., NAD+ boosters) sold through both DTC and clinician channels. It is the closest analogue to Chrysea's positioning of a science-backed, clinically-tested longevity bioactive sold to health-conscious consumers and practitioners.
  • Tally Health: Tally Health markets longevity-focused supplements and biological-age testing directly to consumers and partners. It overlaps with Chrysea in the science-led longevity nutraceutical category targeting the same health-conscious, longevity-curious buyer.
  • Insilico Medicine: Insilico Medicine is a longevity and aging-disease biotech combining AI-driven discovery with internal development pipelines. It is comparable to Chrysea as a science-first longevity company pursuing clinically-validated interventions rather than commodity supplements.
  • BioAge Labs: BioAge Labs develops therapeutics targeting the biology of aging, including metabolic and immune function pathways relevant to longevity. It shares Chrysea's positioning at the intersection of longevity science, immune/metabolic mechanisms, and clinical development.
  • Juvenescence: Juvenescence is a longevity-focused biotech that develops and invests in compounds targeting aging biology. It is comparable as a multi-program longevity company pursuing clinically-validated aging interventions rather than generic supplements.
  • Longeveron: Longeveron is a clinical-stage biotech developing cellular therapies for aging-related and rare diseases. It overlaps with Chrysea in the clinical longevity therapeutics space targeting biological aging mechanisms.
  • Human Longevity Inc. Human Longevity Inc. combines longevity-focused health intelligence, diagnostics, and clinical programs. It is comparable to Chrysea as a science-driven longevity company building premium clinical channels around aging biology.

Broad incumbents

  • Ginkgo Bioworks: Ginkgo Bioworks is a large synthetic biology platform that programs cells for bioactives, flavors, and industrial biotech. It overlaps with Chrysea on the synthetic biology and biomanufacturing capability stack acquired via Rodon Biologics.
  • Codexis: Codexis develops engineered enzymes and biomanufacturing processes for pharmaceuticals and sustainable chemicals. It is comparable to Chrysea/Rodon on the protein engineering and biomanufacturing capability dimension, though serving pharma and industrial customers rather than direct longevity consumers.
  • Novonesis (Novozymes): Novonesis is a global industrial biotechnology leader in enzyme and microbial fermentation-based manufacturing. It is comparable to Chrysea on the fermentation-driven biomanufacturing and protein engineering capability axis, operating at much larger scale across multiple end markets.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

Chrysea social profiles

Digital presence

Chrysea financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Chrysea leadership team

Management profile

Number of profiles

Profiles2 records

Chrysea subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Chrysea funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Chrysea M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Chrysea

What does Chrysea do?

Chrysea develops and commercializes high-purity spermidine-based nutritional interventions targeting aging and longevity. Through its acquired biomanufacturing arm Rodon Biologics, the company produces Sprevive, a proprietary high-purity spermidine complex, which it distributes to healthcare practitioners and pharmacies for clinician-guided care.

Is Chrysea a public or private company?

Chrysea is a private company. It is classified as unknown and is currently operating.

When was Chrysea founded?

Chrysea was founded in 2020. It employs 1 to 10 people.

Where is Chrysea based?

Chrysea is headquartered in Dublin, Ireland, in the Europe region.

Who are Chrysea's main competitors?

Direct peers on record are Elysium Health, Tally Health, Insilico Medicine, BioAge Labs, Juvenescence, Longeveron and Human Longevity Inc.. Broad incumbents are Ginkgo Bioworks, Codexis and Novonesis (Novozymes).

Does Chrysea have an API?

No public API is recorded for Chrysea.

What industry is Chrysea in?

Chrysea's product category is Longevity Biopharmaceuticals. Its primary akta.pro industry code is HLAKAOAD, Male Reproductive & Sexual Medicine (Andrology). Its NAICS code is 325411 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Longevity.TechnologyDeal between Chrysea, nuBioAge brings spermidine to clinicsChrysea Labs and nuBioAge have entered into a partnership to bring Sprevive, a high-purity spermidine complex, into US clinical settings, with nuBioAge receiving exclusive rights to commercialize the product through healthcare practitioners and pharmacies. The deal represents a strategic shift from wellness supplements toward clinician-guided longevity care, emphasizing clinical testing, GRAS recognition, and standardized dosing. Chrysea is simultaneously conducting a study with Mount Sinai researchers to explore how Sprevive supports immune and metabolic function, positioning the product as a bridge between longevity science and evidence-based clinical application.Longevity.TechnologyChrysea acquires Rodon to advance development of nutritional longevity productsChrysea has acquired biomanufacturing firm Rodon Biologics from Iberfar Group to enhance its synthetic biology and biopharma development capabilities. The strategic acquisition integrates Rodon’s proficiency in protein engineering and precision fermentation, aiming to drive capital efficiency for Chrysea while allowing Rodon to continue operating independently. Juvenescence, an investor in Chrysea, supported the transaction.LinkedInChrysea Acquires Rodon Biologics to Strengthen Capabilities in Synthetic Biology and Biopharmaceuticals DevelopmentChrysea has acquired Rodon Biologics to enhance its capabilities in synthetic biology and biopharmaceutical development. This acquisition recognizes Rodon's extensive experience over 20 years, which will add value to Chrysea's projects and improve its engineering and biomanufacturing capabilities. The strategic move aims to address challenges in biomanufacturing and accelerate the commercialization of new bioproducts.PR NewswireJuvenescence joins Banco Português de Fomento and 200M Fund in co-investment in Chrysea LaboratoriesJuvenescence Limited, through its JuvLife Division, has co-invested with the 200M Fund, managed by Banco Português de Fomento, in a venture round for Chrysea Labs, a synthetic biology company developing high-value natural products. Banco Português de Fomento invested €3,721,387.04 in Chrysea, which uses proprietary synthetic biology platforms to produce naturally occurring metabolites that induce autophagy for cellular regeneration in aging individuals. Juvenescence and Chrysea will collaborate to develop and commercialize one of Chrysea's products focused on maintaining cardiovascular, cognitive, and immune function.